Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 2:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Terminated No phase listed Observational Accepts healthy volunteers

Visual Function Tests in Age-related Macular Degeneration

NCT03275753
Conditions
Age Related Macular Degeneration
Interventions
Visual Function Tests
Other
Lead sponsor
ORA, Inc.
Industry
Eligibility
60 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Andover, Massachusetts
Conditions
Maculopathy, Age-Related
Interventions
Anecortave Acetate 15 mg, Triamcinolone Acetate 4 mg, Photodynamic Therapy with Verteporfin, Thermal Laser
Drug · Procedure
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Conditions
Exudative Macular Degeneration
Interventions
Aflibercept
Drug
Lead sponsor
Rishi Singh
Other
Eligibility
50 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Exudative Macular Degeneration
Interventions
TRIPLE COMBINATION THERAPY
Procedure
Lead sponsor
The Retina Center of St. Louis County, PC
Other
Eligibility
50 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Age-Related Maculopathy
Interventions
Lucentis
Drug
Lead sponsor
University of Utah
Other
Eligibility
50 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Santa Barbara, California • Denver, Colorado • Salt Lake City, Utah
Active, not recruiting No phase listed Observational

Impact of Non-Exudative Type 1 MNV on AMD Progression

NCT06125977
Conditions
Age-Related Macular Degeneration, Neovascularization, Choroidal
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
50 Years and older
Enrollment
73 participants
Timeline
2023 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Neovascular Age-Related Macular Degeneration (nAMD)
Interventions
4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
Biological
Lead sponsor
4D Molecular Therapeutics
Industry
Eligibility
50 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
54
States / cities
Scottsdale, Arizona • Sun City, Arizona • Tucson, Arizona + 49 more
Conditions
Age-related Macular Degeneration
Interventions
Ranibizumab 0.5mg
Drug
Lead sponsor
Leonard Feiner, MD, PhD
Other
Eligibility
50 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Teaneck, New Jersey • Vauxhall, New Jersey
Conditions
Age Related Macular Degeneration
Interventions
ranibizumab
Drug
Lead sponsor
The New York Eye & Ear Infirmary
Other
Eligibility
51 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Conditions
Age-Related Macular Degeneration
Interventions
DE-120
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
55 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Bakersfield, California • Beverly Hills, California • Dallas, Texas
Conditions
Macular Degeneration
Interventions
pegaptanib sodium
Drug
Lead sponsor
Eyetech Pharmaceuticals
Industry
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
20
States / cities
Los Angeles, California • Bridgeport, Connecticut • Hamden, Connecticut + 16 more
Conditions
Age-Related Maculopathy
Interventions
Rheopheresis
Device
Lead sponsor
OccuLogix
Industry
Eligibility
50 Years to 85 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 18 more
Conditions
Neovascular (Wet) Age-Related Macular Degeneration
Interventions
4D-150 IVT, Aflibercept IVT
Biological
Lead sponsor
4D Molecular Therapeutics
Industry
Eligibility
50 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
25
States / cities
Phoenix, Arizona • Oxnard, California • Sacramento, California + 21 more
Conditions
Exudative Age Related Macular Degeneration
Interventions
Ranibizumab Injection [Lucentis]
Drug
Lead sponsor
Southeast Clinical Research Associates, LLC
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Charlotte, North Carolina • Statesville, North Carolina
Terminated Phase 2 Interventional Results available

X-82 to Treat Age-related Macular Degeneration

NCT02348359
Conditions
Age-Related Macular Degeneration (AMD), Macular Degeneration, Exudative Age-related Macular Degeneration, AMD, Macular Degeneration, Age-related, 10, Eye Diseases, Retinal Degeneration, Retinal Diseases
Interventions
X-82, Anti-VEGF, Placebo
Drug
Lead sponsor
Tyrogenex
Industry
Eligibility
50 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
35
States / cities
Tucson, Arizona • Beverly Hills, California • Huntington Beach, California + 32 more
Conditions
Age-Related Macular Degeneration
Interventions
PF-04523655
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
8
States / cities
Beverly Hills, California • Pasadena, California • Walnut Creek, California + 5 more
Conditions
Age-Related Macular Degeneration (AMD)
Interventions
PAN-90806 Ophthalmic Solution, Lucentis
Drug
Lead sponsor
PanOptica, Inc.
Industry
Eligibility
50 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
22
States / cities
Colorado Springs, Colorado • Winter Haven, Florida • Shawnee Mission, Kansas + 19 more
Conditions
Age-related Macular Degeneration
Interventions
MT-0814, Placebo
Drug
Lead sponsor
Senju Pharmaceutical Co., Ltd.
Industry
Eligibility
50 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
13
States / cities
Peoria, Arizona • Phoenix, Arizona • Pasadena, California + 10 more
Conditions
Age-Related Macular Degeneration
Interventions
Photodynamic Therapy (PDT) with Visudyne (verteporfin), Macugen (pegaptanib sodium)
Drug
Lead sponsor
Eyetech Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Geographic Atrophy
Interventions
ORACEA®, Placebo
Drug
Lead sponsor
Paul Yates, MD, PhD
Other
Eligibility
55 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
37
States / cities
Glendale, California • Poway, California • Golden, Colorado + 31 more
Conditions
Age Related Macular Degeneration
Interventions
Fluocinolone Acetonide/Medidur
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Age-related Macular Degeneration
Interventions
RBM-007 Injectable Solution
Drug
Lead sponsor
Ribomic USA Inc
Industry
Eligibility
55 Years to 99 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Sacramento, California • Stanford, California • Walnut Creek, California
Completed No phase listed Observational Accepts healthy volunteers

A Single-Center Pilot Study to Assess Macular Function

NCT01204541
Conditions
Macular Degeneration
Interventions
Not listed
Lead sponsor
ORA, Inc.
Industry
Eligibility
20 Years to 90 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Andover, Massachusetts
Conditions
Age-Related Macular Degeneration
Interventions
0.5 mg of DE-122, 1.0 mg of DE-122, 2.0 mg of DE-122, 4.0 mg of DE-122
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
5
States / cities
Mountain View, California • Walnut Creek, California • Jackson, Michigan + 2 more